New drug cocktail aims to tackle Hard-to-Treat myeloma

NCT ID NCT07217184

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a combination of two drugs, belantamab mafodotin and isatuximab, in 30 people with relapsed or refractory multiple myeloma. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have already tried at least three other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin and isatuximab
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1/2) and small (30 people) study. The combination may cause serious side effects like eye problems, low blood counts, or liver issues, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Atlanta, Georgia, 30322, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Grand Rapids, Michigan, 49546, United States
GSK Investigational Site

Madison, Wisconsin, 53792, United States
GSK Investigational Site

Fitzroy, Victoria, 3065, Australia
GSK Investigational Site

Salvador, Estado de Bahia, 41253-190, Brazil
GSK Investigational Site

São Paulo, 04537-080, Brazil
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Athens, 11528, Greece
GSK Investigational Site

Mexico City, 01330, Mexico
GSK Investigational Site

Oslo, 0450, Norway
GSK Investigational Site

Seoul, 06351, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Ulsan, 44033, South Korea
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Pozuelo de AlarcOn Madr, 28223, Spain
GSK Investigational Site

Falun, SE-791 82, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.